Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
Holding RGNX?
Track your performance easily
See the Price Targets and Ratings of:
RGNX Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RGNX Stock 12 Month Forecast
Average Price Target
$34.75
▲(260.85% Upside)
| Highest Price Target$50.00 | Average Price Target$34.75 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Initiated
11/15/24
RBC Capital
Reiterated
11/12/24
Barclays
Reiterated
11/08/24
Stifel Nicolaus
Reiterated
11/07/24
H.C. Wainwright
Reiterated
11/07/24
Robert W. Baird
Reiterated
11/06/24
Leerink Partners
Reiterated
11/06/24
Raymond James
Initiated
10/10/24
Bank of America Securities
Reiterated
08/02/24
Goldman Sachs
Initiated
06/07/24
Chardan Capital
$52
Buy
439.98%
Upside
Reiterated
03/07/24
We note that the only currently approved DMD GT Elevidys is indicated for patients aged 4-5 yrs. Nonetheless, we emphasize that µDys expression levels are highly variable, and presently there is no clear or reliable way to predict which patients are more likely to have more robust µDys expression. Importantly, the company shared video recordings of trial clinic assessments, showing evidence of strength and functional improvement. While encouraging, the recordings represent informal assessments, and detailed strength and functional assessment data for both dose levels are expected in 2H24. RGNX plans to select a pivotal dose in mid-2024 and initiate a pivotal study in 2H24. With the clean safety profile across both DLs to date, with no reported SAEs, we expect the company to advance DL2 into the pivotal studies.
Oppenheimer
$21
Hold
118.07%
Upside
Reiterated
03/05/24
RegenXBio's RGX-202 Hold Rating: Balancing Promising DMD Trial Outcomes with Competitive Market Challenges
UBS
$47→$43
Buy
346.52%
Upside
Reiterated
01/17/24
Regenxbio Inc. (RGNX) PT Lowered to $43 at UBSUBS analyst Esther Rajavelu lowered the price target on Regenxbio Inc. (NASDAQ: RGNX) to $43.00 (from $47.00) while maintaining a Buy rating.
Best Analysts Covering RegenXBio
Which Analyst Should I Follow If I Want to Buy RGNX and Sell After:
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+10.98%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +10.98% per trade.
3 Months
xxx
Success Rate
4/9 ratings generated profit
Average Return
-8.58%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -8.58% per trade.
1 Year
Success Rate
2/7 ratings generated profit
Average Return
-11.23%
reiterated a buy rating 17 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -11.23% per trade.
2 Years
xxx
Success Rate
2/7 ratings generated profit
Average Return
-11.23%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -11.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RGNX Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
13
15
10
10
11
Buy
1
1
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
16
11
11
12
Each month's total comprises the sum of three months' worth of ratings.
RGNX Financial Forecast
RGNX Stock Forecast FAQ
What is RGNX’s average 12-month price target, according to analysts?
Based on analyst ratings, RegenXBio’s 12-month average price target is $34.75.
What is RGNX’s upside potential, based on the analysts’ average price target?
RegenXBio has 260.85% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RGNX a Buy, Sell or Hold?
RegenXBio has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is RegenXBio’s price target?
The average price target for RegenXBio is $34.75. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $18.00. The average price target represents 260.85% Increase from the current price of $9.63.
The highest analyst price target is $50.00 ,the lowest forecast is $18.00. The average price target represents 260.85% Increase from the current price of $9.63.
What do analysts say about RegenXBio?
RegenXBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of RGNX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.